Drug Profile
Research programme: diabetic retinopathy therapeutics - AstraZeneca/UCL
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca; University College London
- Class Biological factors; Small molecules
- Mechanism of Action Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic retinopathy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetic-retinopathy in United Kingdom
- 13 Sep 2010 Early research in Diabetic retinopathy in United Kingdom (unspecified route)